The molecular adsorbents recycling system as a liver support system based on albumin dialysis: A summary of preclinical investigations, prospective, randomized, controlled clinical trial, and clinical experience from 19 centers

Artificial Organs

Volumn 26, Issue 2, 2002, Pages 103-110

  Stange, Jan ^a   Hassanein, Tarek I ^a   Mehta, Ravindra ^a   Mitzner, Steffen R ^b   Bartlett, Robert H ^c  

^a UCSD MEDICAL CENTER   (United States)

^b UNIVERSITY OF ROSTOCK   (Germany)

^c UNIVERSITY OF MICHIGAN HOSPITALS   (United States)

Author keywords

Albumin dialysis; Clinical trials; Liver failure; Liver support; Molecular adsorbents recycling system; Multicenter trials

Indexed keywords

ADSORBENTS; ARTIFICIAL ORGANS; BINDING SITES; DETOXIFICATION; DIALYSIS MEMBRANES; PATIENT TREATMENT; RECYCLING;

ALBUMIN DIALYSIS; CLINICAL TRIAL; LIVER FAILURE; LIVER SUPPORT; MOLECULAR ADSORBENT RECYCLING SYSTEM; MULTICENTER TRIAL; PROSPECTIVES; RECYCLING SYSTEMS; SUPPORT SYSTEMS; SURVIVAL TIME;

DIALYSIS;

ALBUMIN; DIALYSIS FLUID; SOLVENT;

ADULT; ARTICLE; ARTIFICIAL LIVER; BINDING SITE; CHOLESTASIS; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DETOXIFICATION; DIALYSATE; DIALYSIS; DIALYSIS MEMBRANE; FEASIBILITY STUDY; HEMODYNAMICS; HEPATIC ENCEPHALOPATHY; HEPATORENAL SYNDROME; HUMAN; KIDNEY FAILURE; KIDNEY FUNCTION; LIVER FAILURE; LIVER FUNCTION; MENTAL HEALTH; MULTICENTER STUDY; PRIORITY JOURNAL; PRURITUS; RANDOMIZED CONTROLLED TRIAL; RECYCLING; SURVIVAL TIME; TREATMENT OUTCOME;

EID: 0036121240     PISSN: 0160564X     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1525-1594.2002.06822.x     Document Type: Article

References (56)

1. High-permeability membrane hemodialysis and hemofiltration in acute hepatic coma: Experimental and clinical results
2. What is needed for an artificial liver?
3. Solute, amino acid, and hormone changes with coated charcoal hemoperfusion in uremia
4. Complement activation as a cause of transient hypotension during plasmapheresis
5. Postoperative management following massive hepatectomy in a patient with Dubin-Johnson syndrome: Report of a case
6. Massive thyroxine intoxication: Evaluation of plasma extraction
7. Plasma exchange and hemoperfusion in iodine-induced thyrotoxicosis
8. Resin hemoperfusion: A method of removing circulating thyroid hormones
9. Combined hemodialysis-hemoperfusion in the treatment of secondary hyperparathyroidism of uremic patients
10. In vitro and clinical studies of the removal of cortisol, thyroxine, insulin, and thyroid-stimulating hormone by coated charcoal haemoperfusion
11. Influence of hemoperfusion on the concentrations of calcitonin, testosterone and cortisol in blood plasma
12. Clinical effects of a sorbent suspension dialysis system in treatment of hepatic coma (the BioLogic-DT)
13. Clinical experience with artificial liver support in chronic liver failure with encephalopathy
14. Fractionated plasma separation and adsorption system: A novel system for blood purification to remove albumin bound substances
15. Artificial liver
16. Extracorporeal liver support: Cellbased therapy for the failing liver
17. Dialysis against an on line recycled albumin circle enables removal of protein bound toxins
18. Mass transfer of albumin bound toxins through membranes-comparison between hemofiltration and the MARS-system
19. Removal of albumin bound toxins by extended dialysis
20. Characteristics of an albumin dialysate hemodiafiltration system for the clearance of unconjugated bilirubin
21. A carrier-mediated transport of toxins in a hybrid membrane. Safety barrier between a patients blood and a bioartificial liver
22. Role of albumin for transport and distribution of protein bound substances between compartments
23. Improvement of systemic vascular resistance and arterial pressure in patients with acute on chronic liver failure during treatment with the molecular adsorbent recycling system
24. Molecular adsorbent recycling system (MARS) - A new membrane based blood purification system for bioartificial liver support-clinical results
25. Removal of benzodiazepine-like substances as a cause of improvement of hepatic encephalopathy during albumin dialysis
26. Albumin dialysis: Effective removal of copper in a patient with fulminant Wilson disease and successful bridging to liver transplantation: A new possibility for the elimination of protein bound toxins
27. A new procedure for the removal of protein bound drugs and toxins
28. Inhibition of NO synthase by arginine removal by liver support (MARS) seems to be only a cofactor for reversal of hypotension in decompensated liver cirrhosis that seems to be linked more to removal of protein bound toxins
29. Can the clearance of tumor necrosis factor alpha and interleukin 6 be enhanced using an albumin dialysate hemodiafiltration system?
30. The effect of the molecular adsorbent recycling system (MARS) on cerebral perfusion in patients with acute on chronic liver failure and hepatic encephalopathy
31. Evaluation of an extracorporeal liver assist device using selective hemodiafiltration in an animal model of hepatic failure
32. A novel stable reproducible model of hepatic failure in canines
33. Improvement of hepatorenal syndrome with extracorporeal albumin dialysis MARS: Results of a prospective, randomized, controlled clinical trial
34. Liver support by extracorporeal blood purification: A clinical observation
35. Role of molecular adsorbent recycling system (MARS) in the treatment of patients with acute exacerbation of chronic liver failure
36. Results of a phase I trial evaluating an extracorporeal hepatic support device utilizing albumin dialysis
37. Use of MARS in the treatment of acute liver failure: Preliminary monocentric experience
38. MARS for treatment of fulminant Wilson crisis
39. Albumin dialysis with the MARS for a patient with acute liver failure due to paracetamol intoxication: A case report
40. Treatment of split liver recipients with poor graft function by albumin dialysis (MARS)
41. Application of artificial liver support (MARS) after split-liver transplantation in an infant
42. Continous venovenous hemofiltration with extracorporeal albumin dialysis "MARS" in critically ill patients before and after liver transplantation
43. Edouard Herriot experience with the MARS in 5 patients experiencing hepatic failure
44. Successful clinical application of extracorporeal albumin dialysis in a patient with benign recurrent intrahepatic cholestasis (BRIC)
45. One year experience with MARS therapy in patients with multiorgan failure in Cardiac Center Bad Oyenhausen
46. Toxic bile salts induce rodent hepatocyte apoptosis via direct activation of Fas
47. Nitric oxide circulates in mammalian plasma primarily as an s-nitroso adduct of serum albumin
48. The nitric oxide hypothesis and the hyperdynamic circulation in cirrhosis
49. Long term treatment of patients with acute exacerbation of chronic liver failure by albumin dialysis
50. Blood purification in excretory liver insufficiency by albumin dialysis: Impact of the dialysis membrane
51. Efficacy of MARS in 3 patients with hepatorenal syndrome and hepatic encephalopathy: First experience in Spain
52. Motor cortex excitability in severe liver failure: Effects of Molecular Adsorbents Recycling System
53. Artificial liver support as a bridge to orthotopic liver transplantation in a case of acute non-alcoholic steatohepatitis (NASH)
54. MARS in decompensated alcoholic liver disease with multiorgan failure
55. Employment of MARS (Molecular Adsorbents Recycling System) for replacement of liver detoxification function up to orthothopic liver transplantation
56. Molecular Adsorbents Recycling System (MARS) for acute on chronic alcoholic hepatitis: A case report